A Phase 1 interventional study of ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Subcutaneous and ZOSTAVAX™ (Zoster Vaccine Live) 1/3 Dose Subcutaneous in Herpes Zoster, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-06-23.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing Chickenpox Vaccine in Herpes Zoster — none open to participants now, none under way, none of them phase 3. Chickenpox Vaccine · Herpes Zoster.
Among the 29 studies testing Chickenpox Vaccine in Herpes Zoster, this one is the 12th largest by enrollment, is one of 4 that started in 2011, is one of 3 in phase 1, and was the 14th registered.
299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.
Browse Herpes Zoster studies →None of the 29 studies testing Chickenpox Vaccine in Herpes Zoster is open now. The open studies under Herpes Zoster, anywhere →
Chickenpox Vaccine: first FDA approval 1995 (Varivax). What it is approved for, and how studies give it, is on its page →
Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.
This study: 50 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 9 · Phase 4 8
First in 2001; this study’s year is marked. 4 started in 2011.
This study's enrollment of 223 is above the median of 160 across 247 interventional studies indexed under Herpes Zoster.
Median enrollment 160 across the 29 interventional studies. Of the 28 that completed or were terminated, 20 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 29 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
27 studies in Herpes Zoster by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 26 finished, 24 (92%) have results posted.
Among the 27 studies in Herpes Zoster by Merck & Co., Inc, this one is the 18th largest by enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2011, is one of 5 in phase 1, and was the 18th registered.
Merck & Co., Inc’s Herpes Zoster studies by the year they started, since 1995.
None of the studies under way reaches primary completion within a year.
Among the 29 studies testing Chickenpox Vaccine in Herpes Zoster, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 27 in Herpes Zoster:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will compare the safety and immunogenicity of ZOSTAVAX™ (V211) administered both intradermally and subcutaneously at various doses.
This is an exploratory, randomized, partially blinded, multicenter clinical study designed to compare safety and biomarkers of varicella zoster virus immunogenicity when administering ZOSTAVAX™ (V211) at various doses both intradermally and subcutaneously in healthy male and female participants 50 years of age and older.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a full dose of ZOSTAVAX™ administered subcutaneously on Day 1 of the study. Nine participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1.
Biological: ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Subcutaneous · Biological: Intradermal Placebo
Participants will receive a 1/3 dose of ZOSTAVAX™ administered subcutaneously on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.
Biological: ZOSTAVAX™ (Zoster Vaccine Live) 1/3 Dose Subcutaneous · Biological: Intradermal Placebo
Participants will receive a full dose of ZOSTAVAX™ administered intradermally on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.
Biological: ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Intradermal · Biological: Full Dose Intradermal Placebo
Participants will receive a 1/3 dose of ZOSTAVAX™ administered intradermally on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.
Biological: ZOSTAVAX™ (Zoster Vaccine Live) Partial Doses Intradermal · Biological: Intradermal Placebo
Participants will receive a 1/10 dose of ZOSTAVAX™ administered intradermally on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.
Biological: ZOSTAVAX™ (Zoster Vaccine Live) Partial Doses Intradermal · Biological: Intradermal Placebo
Participants will receive a 1/27 dose of ZOSTAVAX™ administered intradermally on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.
Biological: ZOSTAVAX™ (Zoster Vaccine Live) Partial Doses Intradermal · Biological: Intradermal Placebo
One 0.65 mL injection subcutaneously on Day 1
Also known as: V211
Drug page: Chickenpox Vaccine
One approximately 0.22 mL injection subcutaneously on Day 1
Also known as: V211
Two intradermal injections of approximately 0.15 mL each on Day 1
Also known as: V211
One intradermal injection of approximately 0.1 mL on Day 1
Also known as: V211
Two intradermal placebo injections of approximately 0.15 mL each on Day 1
One intradermal placebo injection of approximately 0.1 mL on Day 1
Geometric Mean Fold Change From Baseline in Varicella Zoster Virus (VZV)-Specific Antibodies
VZV antibody titers were measured by glycoprotein enzyme-linked immunosorbent assay at baseline and at 6 weeks after vaccine administration. The geometric mean fold change represents the 6-week value / the baseline value.
Time frame: Baseline and 6 weeks following vaccine administration
Number of Participants Reporting an Adverse Experience (AE)
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an adverse experience.
Time frame: Up to 42 days following vaccine administration
Number of Participants Reporting a Serious Adverse Experience (SAE)
An SAE is any adverse experience that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in or prolongs an existing inpatient hospitalization, is a congenital anomaly/birth defect in offspring of a study participant, is a cancer, or is another important medical event when, based on appropriate medical judgment, the event may jeopardize the participant and may require medical or surgical intervention.
Time frame: Up to 42 days following vaccine administration
Number of Participants Reporting a Serious Adverse Experience
An SAE is any adverse experience that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in or prolongs an existing inpatient hospitalization, is a congenital anomaly/birth defect in offspring of a study participant, is a cancer, or is another important medical event when, based on appropriate medical judgment, the event may jeopardize the participant and may require medical or surgical intervention
Time frame: Within 5 days after the blood draw at approximately 20 months following vaccine administration
Number of Participants Reporting Specific Local Injection-site Adverse Experiences Prompted for on the Vaccine Report Card (VRC)
The VRC actively prompts for local injection-site AEs of redness, swelling, and pain/tenderness and for the size of local injection-site reactions of redness and swelling that occur within 5 days of vaccination. The presence of varicella/varicella-like rash and herpes zoster/herpes zoster-like rash is also captured on the VRC. Participants receiving an injection in both limbs will be instructed to complete injection-site reaction information for each limb. All injection-site AEs were reported for the limb in which they occurred: V211 vaccine or placebo.
Time frame: Up to 5 days following vaccine administration
Number of Participants Reporting Systemic Adverse Experiences
Systemic AEs included all reported AEs except injection-site AEs
Time frame: Up to 42 days following vaccine administration
Number of Participants Reporting a Non-injection-site Rash (Varicella, Varicella-like, Herpes Zoster, or Herpes Zoster-like)
Non-injection-site rashes were examined by a study physician. Rashes suspected to be varicella/varicella-like or herpes zoster/herpes zoster-like were sampled for verification by polymerase chain reaction.
Time frame: Up to 42 days following vaccine administration
| Milestone | Full Dose Subcutaneous | 1/3 Dose Subcutaneous | Full Dose Intradermal | 1/3 Dose Intradermal | 1/10 Dose Intradermal | 1/27 Dose Intradermal |
|---|---|---|---|---|---|---|
| Started | 52 | 34 | 34 | 35 | 34 | 34 |
| Completed | 51 | 34 | 34 | 34 | 34 | 34 |
| Not completed | 1 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 0 | 0 |
VZV antibody titers were measured by glycoprotein enzyme-linked immunosorbent assay at baseline and at 6 weeks after vaccine administration. The geometric mean fold change represents the 6-week value / the baseline value.
| Geometric mean fold change | Full Dose Subcutaneous | 1/3 Dose Subcutaneous | Full Dose Intradermal | 1/3 Dose Intradermal | 1/10 Dose Intradermal | 1/27 Dose Intradermal |
|---|---|---|---|---|---|---|
| Geometric Mean Fold Change From Baseline in Varicella Zoster Virus (VZV)-Specific Antibodies | 1.74 (1.48 to 2.05) | 1.64 (1.35 to 2.00) | 3.24 (2.66 to 3.94) | 2.45 (2.02 to 2.97) | 2.21 (1.82 to 2.69) | 1.64 (1.35 to 2.00) |
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an adverse experience.
| participants | Full Dose Subcutaneous | 1/3 Dose Subcutaneous | Full Dose Intradermal | 1/3 Dose Intradermal | 1/10 Dose Intradermal | 1/27 Dose Intradermal |
|---|---|---|---|---|---|---|
| Number of Participants Reporting an Adverse Experience (AE) | 30 | 10 | 27 | 23 | 21 | 19 |
An SAE is any adverse experience that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in or prolongs an existing inpatient hospitalization, is a congenital anomaly/birth defect in offspring of a study participant, is a cancer, or is another important medical event when, based on appropriate medical judgment, the event may jeopardize the participant and may require medical or surgical intervention.
| participants | Full Dose Subcutaneous | 1/3 Dose Subcutaneous | Full Dose Intradermal | 1/3 Dose Intradermal | 1/10 Dose Intradermal | 1/27 Dose Intradermal |
|---|---|---|---|---|---|---|
| Number of Participants Reporting a Serious Adverse Experience (SAE) | 0 | 0 | 0 | 0 | 0 | 0 |
An SAE is any adverse experience that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in or prolongs an existing inpatient hospitalization, is a congenital anomaly/birth defect in offspring of a study participant, is a cancer, or is another important medical event when, based on appropriate medical judgment, the event may jeopardize the participant and may require medical or surgical intervention
| Participants | Full Dose Subcutaneous | 1/3 Dose Subcutaneous | Full Dose Intradermal | 1/3 Dose Intradermal | 1/10 Dose Intradermal | 1/27 Dose Intradermal |
|---|---|---|---|---|---|---|
| Number of Participants Reporting a Serious Adverse Experience | 0 | 0 | 0 | 0 | 0 | 0 |
The VRC actively prompts for local injection-site AEs of redness, swelling, and pain/tenderness and for the size of local injection-site reactions of redness and swelling that occur within 5 days of vaccination. The presence of varicella/varicella-like rash and herpes zoster/herpes zoster-like rash is also captured on the VRC. Participants receiving an injection in both limbs will be instructed to complete injection-site reaction information for each limb. All injection-site AEs were reported for the limb in which they occurred: V211 vaccine or placebo.
| Participants | Full Dose Subcutaneous | 1/3 Dose Subcutaneous | Full Dose Intradermal | 1/3 Dose Intradermal | 1/10 Dose Intradermal | 1/27 Dose Intradermal | Placebo |
|---|---|---|---|---|---|---|---|
| Any injection-site AE | 27 | 7 | 27 | 22 | 19 | 19 | 5 |
| Injection-site anaesthesia | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Injection-site erythema | 16 | 5 | 26 | 20 | 16 | 18 | 4 |
| Injection-site haematoma | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Injection-site induration | 5 | 2 | 12 | 12 | 11 | 10 | 1 |
| Injection-site pain | 15 | 5 | 8 | 9 | 5 | 6 | 0 |
| Injection-site pruritus | 1 | 2 | 3 | 3 | 1 | 1 | 0 |
| Injection-site rash | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Injection-site scab | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Injection-site swelling | 13 | 4 | 13 | 8 | 6 | 7 | 2 |
Systemic AEs included all reported AEs except injection-site AEs
| participants | Full Dose Subcutaneous | 1/3 Dose Subcutaneous | Full Dose Intradermal | 1/3 Dose Intradermal | 1/10 Dose Intradermal | 1/27 Dose Intradermal |
|---|---|---|---|---|---|---|
| Number of Participants Reporting Systemic Adverse Experiences | 12 | 6 | 6 | 4 | 5 | 6 |
Non-injection-site rashes were examined by a study physician. Rashes suspected to be varicella/varicella-like or herpes zoster/herpes zoster-like were sampled for verification by polymerase chain reaction.
| participants | Full Dose Subcutaneous | 1/3 Dose Subcutaneous | Full Dose Intradermal | 1/3 Dose Intradermal | 1/10 Dose Intradermal | 1/27 Dose Intradermal |
|---|---|---|---|---|---|---|
| Number of Participants Reporting a Non-injection-site Rash (Varicella, Varicella-like, Herpes Zoster, or Herpes Zoster-like) | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over Serious Adverse Events were collected up to 20 months following vaccine administration. Other Adverse Events were collected up to 84 days following vaccine administration.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Full Dose Subcutaneous | — | 0/52 (0%) | 30/52 (57.7%) |
| 1/3 Dose Subcutaneous | — | 0/34 (0%) | 10/34 (29.4%) |
| Full Dose Intradermal | — | 0/34 (0%) | 27/34 (79.4%) |
| 1/3 Dose Intradermal | — | 0/35 (0%) | 23/35 (65.7%) |
| 1/10 Dose Intradermal | — | 0/34 (0%) | 21/34 (61.8%) |
| 1/27 Dose Intradermal | — | 0/34 (0%) | 19/34 (55.9%) |
| Placebo | — | 0/39 (0%) | 5/39 (12.8%) |
| Event | Full Dose Subcutaneous | 1/3 Dose Subcutaneous | Full Dose Intradermal | 1/3 Dose Intradermal | 1/10 Dose Intradermal | 1/27 Dose Intradermal | Placebo |
|---|---|---|---|---|---|---|---|
| Injection site erythemaGeneral disorders | 16/52 | 5/34 | 26/34 | 21/35 | 16/34 | 18/34 | 4/39 |
| Injection site swellingGeneral disorders | 13/52 | 4/34 | 13/34 | 8/35 | 6/34 | 7/34 | 2/39 |
| Injection site indurationGeneral disorders | 5/52 | 2/34 | 12/34 | 12/35 | 11/34 | 10/34 | 1/39 |
| Injection site painGeneral disorders | 15/52 | 5/34 | 8/34 | 9/35 | 5/34 | 6/34 | 0/39 |
| Injection site pruritusGeneral disorders | 1/52 | 2/34 | 4/34 | 4/35 | 1/34 | 1/34 | 0/39 |
| HeadacheNervous system disorders | 1/52 | 2/34 | 2/34 | 0/35 | 3/34 | 0/34 | — |
| NasopharyngitisInfections and infestations | 1/52 | 0/34 | 1/34 | 1/35 | 2/34 | 2/34 | — |
| CoughRespiratory, thoracic and mediastinal disorders | 0/52 | 0/34 | 0/34 | 1/35 | 2/34 | 0/34 | — |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/52 | 0/34 | 0/34 | 0/35 | 2/34 | 0/34 | — |
| Age, Continuous(years) | Full Dose Subcutaneous | 1/3 Dose Subcutaneous | Full Dose Intradermal | 1/3 Dose Intradermal | 1/10 Dose Intradermal | 1/27 Dose Intradermal | Total |
|---|---|---|---|---|---|---|---|
| Mean | 59.9 ± 7.7 | 60.5 ± 7.5 | 62.1 ± 8.5 | 61.2 ± 8.7 | 61.6 ± 8.1 | 60.1 ± 7.1 | 60.8 ± 7.9 |
| Sex: Female, Male(Participants) | Full Dose Subcutaneous | 1/3 Dose Subcutaneous | Full Dose Intradermal | 1/3 Dose Intradermal | 1/10 Dose Intradermal | 1/27 Dose Intradermal | Total |
|---|---|---|---|---|---|---|---|
| Female | 31 | 20 | 17 | 17 | 16 | 24 | 125 |
| Male | 21 | 14 | 17 | 18 | 18 | 10 | 98 |
No study locations are listed for this record.
The record gives a start of Sep 2011, a primary completion of May 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Chickenpox Vaccine